Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
agenT-797
- Development stage
- Phase 3
- Lead developer
- MiNK Therapeutics
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
AgenT-797 is an allogeneic, off-the-shelf cell therapy composed of invariant natural killer T (iNKT) cells derived from healthy donors. These iNKT cells are expanded ex vivo and administered to patients without the need for HLA matching or lymphodepletion. The therapy is designed to directly kill cancer cells and enhance both innate and adaptive immune responses against tumors, including in settings refractory to immune checkpoint inhibitors. AgenT-797 has demonstrated a favorable safety profile with no severe cytokine release syndrome or neurotoxicity in clinical trials. It has shown clinical activity as monotherapy and in combination with anti-PD-1 agents across various solid tumors, including gastric cancer and non-small-cell lung cancer[1][4][7][8].
- Other names
- allogeneic invariant natural killer T cellsiNKT cell therapy
02
Targets
CD1D (Tumor-associated macrophage/myeloid-derived suppressor cell CD1d complex)
Beyond the preview
Go deeper on agenT-797.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on agenT-797.